1 Answers
Estradiol/estradiol enanthate is an injectable combination formulation of estradiol , a short-acting estrogen, and estradiol enanthate , a long-acting estrogen, which was developed by Boehringer around 1960 for potential medical use but was never marketed. It contained 1 mg E2 and 9 mg E2-EN in oil solution and was intended for administration by intramuscular injection.
A single intramuscular injection of E2/E2-EN has been found to result in a 10-fold increase in estradiol excretion on the 2nd day post-injection. Following this, estradiol excretion remained above the menstrual-cycle average for 10 days post-injection and did not return to baseline until the 24th day post-injection.
E2/E2-EN is similar to estradiol benzoate/estradiol phenylpropionate , another injectable combination medication of a shorter-acting estrogen and a longer-acting estrogen. In contrast to E2/E2-EN however, estradiol benzoate/estradiol phenylpropionate was marketed for medical use.